PROteolysis Targeting Chimera Market

A proteolysis targeting chimera (PROTAC) is a heterobifunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.
PROteolysis Targeting Chimera Market contains market size and forecasts of PROteolysis Targeting Chimera (PROTAC) in global, including the following market information:
Global PROteolysis Targeting Chimera (PROTAC) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global PROteolysis Targeting Chimera (PROTAC) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five PROteolysis Targeting Chimera (PROTAC) companies in 2021 (%)
The global PROteolysis Targeting Chimera (PROTAC) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ARV-110 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of PROteolysis Targeting Chimera (PROTAC) include Arvinas, Kymera, C4 therapeutics, Captor therapeutics, Vividion, Cullgen, Pfizer, Merck and Genentech, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the PROteolysis Targeting Chimera (PROTAC) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PROteolysis Targeting Chimera (PROTAC) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global PROteolysis Targeting Chimera (PROTAC) Market Segment Percentages, by Type, 2021 (%)
ARV-110
ARV-471
KYM-001
Others
Global PROteolysis Targeting Chimera (PROTAC) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global PROteolysis Targeting Chimera (PROTAC) Market Segment Percentages, by Application, 2021 (%)
Oncology
Others
Global PROteolysis Targeting Chimera (PROTAC) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global PROteolysis Targeting Chimera (PROTAC) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies PROteolysis Targeting Chimera (PROTAC) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies PROteolysis Targeting Chimera (PROTAC) revenues share in global market, 2021 (%)
Key companies PROteolysis Targeting Chimera (PROTAC) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies PROteolysis Targeting Chimera (PROTAC) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer